Clinical trials: Major Adverse Cardiac Event (MACE)
Obesity, Overweight
Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)
The purpose of this study is to determine the effects of NB relative to placebo on major adverse cardiovascular events (MACE) such as cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in overweight and…
- Trial name
- NCT01601704
- Testing
- NB32, PBO, Weight Management Program
- Where
- 224 sites in United States
- Volunteers
- 8,910 people
- Sponsor
- Orexigen Therapeutics, Inc
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function.
- Trial name
- NCT06383390
- Testing
- Retatrutide
- Where
- 742 sites in United States, Argentina and 25 more
- Volunteers
- 10,000 people
- Sponsor
- Eli Lilly and Company
Myocardial Injury After Non-cardiac Surgery, Urologic Cancer
Prediction of Myocardial Injury After Non-Cardiac Surgery in Urologic Cancer Patients
This prospective multicenter observational study aims to evaluate the predictive value of artificial intelligence-based analysis of preoperative 12-lead electrocardiography for myocardial injury after non-cardiac surgery (MINS)…
- Conditions
- Myocardial Injury After Non-cardiac Surgery, Urologic Cancer, Major Adverse Cardiovascular Events (MACE)
- Trial name
- URO-MINS (NCT07634666)
- Testing
- No intervention assigned
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Korea University Anam Hospital
Coronary Artery Disease, CABG
The 10-Year Extended Follow-up of the DACAB Trial
The goal of this observational study is to learn about the very long-term effects of different antiplatelet strategies in patients who underwent coronary artery bypass grafting (CABG) and participated in the original DACAB trial.
- Conditions
- Coronary Artery Disease, CABG, Antiplatelet Therapy of Coronary Artery Bypass
- Trial name
- DACAB-FE-10Y (NCT07480629)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Ruijin Hospital
Non-ST Elevation Myocardial Infarction (NSTEMI), Acute Coronary Syndrome
Left Atrial Strain for Predicting MACE in NSTEMI
This prospective observational study aims to evaluate whether left atrial reservoir strain, measured by two-dimensional speckle tracking echocardiography, independently predicts 6-month major adverse cardiovascular events (MACE)…
- Conditions
- Non-ST Elevation Myocardial Infarction (NSTEMI), Acute Coronary Syndrome, Myocardial Infarction
- Trial name
- NCT07797634
- Volunteers
- 150 people
- Sponsor
- Assiut University
Coronary Artery Disease, Coronary Artery Bypass Grafting
CCTA-Based vs CAG-Based CABG: A Multicenter Pragmatic Non-Inferiority Trial
The goal of this clinical trial is to find out if using a non-invasive heart scan (called coronary computed tomography angiography, or CCTA) to plan coronary artery bypass grafting (CABG) works as well as the standard invasive…
- Conditions
- Coronary Artery Disease, Coronary Artery Bypass Grafting, Coronary Computed Tomography Angiography, Coronary Angiography (CAG)
- Trial name
- CtaCAB (NCT07769008)
- Testing
- CCTA-based CABG, CAG-based CABG
- Where
- China
- Volunteers
- 826 people
- Sponsor
- Ruijin Hospital
Myocardial Infarction, Myocardial Injury
Colchicine Prevents Myocardial Injury After Non-Cardiac Surgery Pilot Study
Perioperative Myocardial Infarction (PMI) is a major contributor to perioperative mortality and morbidity with overall incidence of 5-16%.
- Conditions
- Myocardial Infarction, Myocardial Injury, Major Adverse Cardiac Events, Infectious Complications
- Trial name
- COPMAN (NCT04139655)
- Testing
- Colchicine 0.6 mg
- Where
- Canada
- Sponsor
- University of British Columbia
Ischemic Heart Disease, Stenotic Coronary Lesion
RESOLUTE ONYX China Single Arm Study
It is a single arm clinical evaluation of safety and efficacy of the Medtronic Resolute Onyx™ zotarolimus-eluting coronary stent system in subjects who are eligible for percutaneous transluminal coronary angioplasty (PTCA) in de…
- Conditions
- Ischemic Heart Disease, Stenotic Coronary Lesion, Cardiovascular Diseases, Arteriosclerosis
- Trial name
- NCT03471845
- Testing
- Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
- Where
- China
- Volunteers
- 591 people
- Sponsor
- Medtronic Vascular
Ischemic Heart Disease, Stenotic Coronary Lesion
China Resolute Integrity 34/38 mm Study
To evaluate the clinical safety and efficacy in Chinese subjects, eligible for percutaneous transluminal coronary angioplasty (PTCA) in lesions amenable to treatment with a 34/38 mm Medtronic Resolute Integrity™…
- Conditions
- Ischemic Heart Disease, Stenotic Coronary Lesion, Cardiovascular Diseases, Arteriosclerosis
- Trial name
- NCT03118531
- Testing
- Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System(34/38 mm)
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Medtronic Vascular
MACE, Atrial Fibrillation (AF)
throMboembolic Risk Associated To High atrIal Fibrillation riSk
Cardiovascular diseases are the leading cause of mortality from treatable conditions in the European Union and the second from preventable causes, with a standardized mortality rate of 257.8 deaths per 100,000 inhabitants.
- Conditions
- MACE, Atrial Fibrillation (AF), Quality-adjusted Life-years, Electronic Health Records
- Trial name
- MATHIAS (NCT07441759)
- Testing
- AI_MATHIAS
- Where
- Spain
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Left Ventricular Remodeling, Plasma Multi-Omics
Prediction of LVAR and MACE in STEMI Though Plasma Multiomics Analysis
To identify plasma multi-omics biomarkers that predict left ventricular adverse remodeling (LVAR) and major adverse cardiovascular events (MACE) in patients with acute ST-segment elevation myocardial infarction, and to…
- Conditions
- Left Ventricular Remodeling, Plasma Multi-Omics, Acute ST-segment Elevation Myocardial Infarction, Immunomics
- Trial name
- NCT06885619
- Testing
- Diagnostic Test: echocardiography and blood collection
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Beijing Anzhen Hospital